“We are pleased that the government has declined at this time to intervene in the qui tam action,” said MiMedx Chairman and CEO Parker H. Petit. “We appreciate the expediency, professionalism and thoroughness with which the OIG conducted its investigation.”
Here are six key notes:
1. There was qui tam action brought against MiMedx several months ago and the Department of Justice declined to intervene.
2. The Department of Health and Human Services, Office of the Inspector General issued a subpoena to MiMedx a few months ago and the company cooperated with the government in responding to the subpoena.
3. MiMedx identified a compliance issue about 20 months ago and terminated the responsible individual within 24 hours.
4. MiMedx provided the government with more than 100,000 lines of electronic data in an effort to expedite the investigative process.
5. The company plans to continue to cooperate with the government on any other requests.
6. MiMedx continues to deny any wrongdoing that would support qui tam action.
More articles on orthopedic devices:
DJO Global to launch Exprt Precision System for knee revisions
Intellijoint Surgical to introduce hip surgery tool in the U.S.
10 things to know about the PRP market through 2020
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
